Short Communication - (2026) Volume 10, Issue 1
Received: 01-Feb-2026, Manuscript No. cmcr-25-186125;
Editor assigned: 03-Feb-0026, Pre QC No. P-186125;
Reviewed: 17-Feb-2026, QC No. Q-186125;
Revised: 23-Feb-2026, Manuscript No. R-186125;
Published:
02-Mar-2026
, DOI: 10.37421/2684-4915.2025.9.421
Citation: Maseko, Sipho. ”Advances In Cancer Immunotherapy: Biomarkers And Resistance.” Clin Med Case Rep 10 (2026):422.
Copyright: © 2026 Maseko S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution and reproduction in any medium, provided the original author and source are credited.
The field of oncology has been significantly transformed by the advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), which have revolutionized the treatment of various advanced malignancies. These therapies work by releasing the brakes on the immune system, allowing T cells to recognize and attack cancer cells more effectively. Numerous studies have explored the efficacy of these agents across a spectrum of cancers, yielding promising results and establishing new standards of care. In non-small cell lung cancer (NSCLC), a critical area of research has focused on identifying biomarkers that predict response to immunotherapy. For instance, the prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs) in patients with advanced NSCLC treated with nivolumab has been investigated, revealing a strong association between high CD8+ TIL density and improved progression-free survival (PFS) and overall survival (OS). This suggests that TILs may serve as a valuable predictive biomarker for immunotherapy response in this challenging disease [1].
Urothelial carcinoma, another significant cancer type, has also benefited from advancements in immunotherapy. The efficacy and safety of atezolizumab in previously treated patients with metastatic urothelial carcinoma have been examined, demonstrating durable responses and a manageable safety profile. These findings support the use of atezolizumab in this patient population, offering a new therapeutic option for those who have progressed on prior treatments [2].
Hepatocellular carcinoma (HCC), a primary liver cancer, presents unique treatment challenges, especially in its unresectable, locally advanced stages. A case report highlights the successful treatment of such a case using transarterial chemoembolization (TACE) combined with nivolumab. This combination therapy showed promising activity in controlling tumor progression and improving patient outcomes, suggesting a potential synergistic approach for managing advanced HCC [3].
Melanoma, a notoriously aggressive skin cancer, has been a frontrunner in the application of immunotherapy. A notable case report describes a patient with metastatic melanoma who achieved a long-term complete response with the combination of ipilimumab and nivolumab. This case underscores the potential of dual immune checkpoint blockade to induce durable responses in advanced melanoma, a significant achievement for patients with limited treatment options [4].
Beyond direct therapeutic applications, the development of novel biomarkers is crucial for optimizing cancer management. Circulating tumor DNA (ctDNA) has emerged as a next-generation biomarker for non-invasively monitoring treatment response and detecting minimal residual disease across various cancers. ctDNA analysis holds substantial promise for personalized cancer management and early detection of relapse, enabling timely adjustments to treatment strategies [5].
In the context of melanoma treatment, further research has explored sequential therapy approaches. The effectiveness of pembrolizumab in patients with advanced unresectable melanoma who had previously been treated with ipilimumab has been evaluated. This study demonstrated that pembrolizumab can achieve significant clinical benefit in this refractory population, offering hope for patients who have exhausted other treatment avenues [6].
More recent advancements have also seen the exploration of combination therapies for rare but aggressive cancers. A case report details a patient with metastatic basal cell carcinoma who achieved a complete response with a combination of vismodegib, a targeted therapy, and cemiplimab, an immunotherapy. This suggests a potential synergistic effect between targeted therapy and immunotherapy, opening new avenues for treatment in this patient group [7].
In NSCLC, specifically in unresectable stage III disease following chemoradiotherapy, durvalumab has emerged as a critical consolidation therapy. A study demonstrated a significant improvement in PFS and OS, establishing durvalumab as a standard of care for patients with unresectable stage III NSCLC who have completed chemoradiotherapy. This represents a major breakthrough in improving outcomes for this patient subgroup [8].
Renal cell carcinoma (RCC) has also witnessed a paradigm shift with the introduction of immunotherapy. A review of current progress and future directions in immunotherapy for advanced RCC highlights the evolving treatment landscape, focusing on immune checkpoint inhibitors like nivolumab and pembrolizumab. The review emphasizes the growing importance of biomarkers in guiding treatment decisions and predicting patient response in this complex disease [9].
The growing success of ICIs has also brought to light the challenge of resistance mechanisms. Understanding the intricate ways in which tumors develop resistance to immunotherapy is paramount for developing more effective treatment strategies. Research into the mechanisms of resistance to immune checkpoint inhibitors and exploring strategies to overcome them is an active and crucial area of investigation, covering both intrinsic and acquired resistance [10].
The clinical application of immune checkpoint inhibitors (ICIs) has profoundly reshaped the therapeutic landscape for many advanced cancers, offering unprecedented treatment options and improved prognoses for patients. These therapies, by modulating the immune system, have demonstrated remarkable efficacy in diseases that were previously considered intractable. In advanced non-small cell lung cancer (NSCLC), the predictive value of tumor microenvironment characteristics is under intense scrutiny. Studies have meticulously examined the prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs) in patients with advanced NSCLC undergoing nivolumab treatment. The findings are compelling, indicating that a higher density of CD8+ TILs correlates with enhanced progression-free survival (PFS) and overall survival (OS), thus positioning TILs as a potential predictive biomarker for immunotherapy responsiveness [1].
The management of metastatic urothelial carcinoma has also seen significant advancements through immunotherapy. Research has focused on evaluating the efficacy and safety profile of atezolizumab in patients who have received prior treatments. The results suggest that atezolizumab can induce durable responses and is associated with a manageable safety profile, reinforcing its role as a valuable therapeutic agent for this patient cohort [2].
For patients diagnosed with unresectable, locally advanced hepatocellular carcinoma (HCC), treatment options are often limited. A compelling case report details a successful treatment regimen involving the combination of transarterial chemoembolization (TACE) and nivolumab. This combined approach demonstrated notable activity in controlling tumor progression and improving the patient's overall outcome, hinting at the potential benefits of multimodal therapies in advanced HCC [3].
In the realm of metastatic melanoma, immunotherapy has achieved remarkable successes. One case report vividly illustrates the potential of dual immune checkpoint blockade, showcasing a patient who experienced a long-term complete response following treatment with ipilimumab and nivolumab. This outcome highlights the capacity of combining these agents to achieve durable remissions in advanced melanoma [4].
The pursuit of non-invasive biomarkers to guide cancer treatment is a critical area of ongoing research. Circulating tumor DNA (ctDNA) has emerged as a promising next-generation biomarker, offering a means to monitor treatment response and detect minimal residual disease without invasive procedures. The application of ctDNA analysis is poised to enhance personalized cancer management and facilitate early identification of disease recurrence [5].
Further investigations into melanoma treatment have explored the effectiveness of sequential immunotherapy. The efficacy of pembrolizumab in advanced unresectable melanoma patients who had previously undergone ipilimumab therapy has been assessed. The results indicate that pembrolizumab can deliver substantial clinical benefits even in this population with refractory disease, providing a crucial option for treatment-resistant melanoma [6].
Innovative treatment strategies are also being explored for other challenging cancers. A case report documents a patient with metastatic basal cell carcinoma who achieved a complete response through a combination of vismodegib, a targeted therapy, and cemiplimab, an immunotherapy. This combination suggests a potential synergistic effect between targeted agents and immune modulators, paving the way for novel therapeutic combinations [7].
In the management of unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy, durvalumab has demonstrated significant value as consolidation therapy. A pivotal study revealed that durvalumab significantly improves progression-free survival and overall survival, solidifying its position as a standard of care for this patient group, thereby enhancing long-term outcomes [8].
The treatment paradigm for advanced renal cell carcinoma (RCC) has been profoundly altered by immunotherapy. A comprehensive review consolidates the progress and future directions of immunotherapy for advanced RCC, with a particular focus on immune checkpoint inhibitors such as nivolumab and pembrolizumab. This review underscores the evolving treatment strategies and the increasing recognition of biomarker utility in this disease [9].
Despite the remarkable successes of ICIs, the development of resistance remains a significant clinical challenge. Understanding the complex mechanisms underlying resistance to these therapies is essential for developing strategies to overcome them. Ongoing research is dedicated to elucidating these mechanisms and devising innovative approaches to enhance the effectiveness of immunotherapy [10].
This collection of research highlights significant advancements in cancer immunotherapy, focusing on immune checkpoint inhibitors (ICIs) like nivolumab, atezolizumab, pembrolizumab, and durvalumab. Studies explore their efficacy and predictive biomarkers in various cancers, including non-small cell lung cancer (NSCLC), urothelial carcinoma, hepatocellular carcinoma (HCC), melanoma, and renal cell carcinoma (RCC). Key findings include the prognostic role of CD8+ tumor-infiltrating lymphocytes (TILs) in NSCLC, durable responses with atezolizumab in urothelial carcinoma, and successful combination therapies in HCC and melanoma. The emergence of circulating tumor DNA (ctDNA) as a non-invasive biomarker is also discussed, alongside strategies to overcome resistance to ICIs. Overall, these studies underscore the transformative impact of immunotherapy and the ongoing efforts to refine its application and overcome treatment challenges.
None
None
Clinical and Medical Case Reports received 53 citations as per Google Scholar report
